ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.47 CNY | -1.32% |
|
-3.25% | -11.49% |
| Jun. 27 | CONBA Pharma's Unit Gets Nod to Market Antidepressant Drug; Shares Down 3% | MT |
| Jun. 27 | CONBA Pharmaceutical Gets Nod to Market Tadalafil Tablets; Shares Down 3% | MT |
| Sales 2024 * | 7.53B 1.04B | Sales 2025 * | 8.73B 1.2B | Capitalization | 11.37B 1.56B |
|---|---|---|---|---|---|
| Net income 2024 * | 752M 103M | Net income 2025 * | 884M 122M | EV / Sales 2024 * | 1.51 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
15.2
x | P/E ratio 2025 * |
12.9
x | Employees | 8,411 |
| Yield 2024 * |
4.25% | Yield 2025 * |
4.59% | Free-Float | 59.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.32% | ||
| 1 week | -3.25% | ||
| 1 month | -10.78% | ||
| 3 months | -8.40% | ||
| 6 months | -13.37% | ||
| Current year | -11.49% |
1 week
4.44
4.62
1 month
4.445.54
Current year
4.075.54
1 year
4.076.66
3 years
3.837.44
5 years
3.838.30
10 years
3.8313.19
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Liang Luo
PSD | President | 62 | 20-07-21 |
Ming Chen
DFI | Director of Finance/CFO | 48 | 20-07-21 |
Zhen Xian Yuan
BRD | Director/Board Member | 48 | 18-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ji Qiang Hu
CHM | Chairman | 63 | 05-04-28 |
Ming Chen
DFI | Director of Finance/CFO | 48 | 20-07-21 |
Zhen Xian Yuan
BRD | Director/Board Member | 48 | 18-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 114 M€ | +7.19% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 4.47 | -1.32% | 18 900 900 |
| 24-07-02 | 4.53 | -1.31% | 29,207,470 |
| 24-07-01 | 4.59 | +2.68% | 39,907,370 |
| 24-06-28 | 4.47 | +0.45% | 34,592,420 |
| 24-06-27 | 4.45 | -3.47% | 48,941,700 |
End-of-day quote Shanghai S.E., July 02, 2024
More quotes
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.47
CNY
Average target price
7.27
CNY
Spread / Average Target
+62.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.49% | 1.59B | |
| +21.80% | 43.81B | |
| +30.40% | 23.03B | |
| +21.32% | 15.45B | |
| +19.05% | 14.4B | |
| +58.92% | 12.95B | |
| -0.05% | 6.79B | |
| -11.84% | 6.49B | |
| -8.87% | 5.73B | |
| +13.00% | 5.49B |
- Stock Market
- Equities
- 600572 Stock
